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Levetiracetam (LEV) is an antiepileptic drug that is clinically effective in generalized and partial epilepsy syndromes.The use of this
drug has been increasing in clinical practice and intra- or -interindividual variability has been exhibited for special population. For
this reason, bioanalytical methods are required for drugmonitoring in biologicalmatrices. So this work presents a dispersive liquid-
liquid microextraction method followed by gas chromatography-mass spectrometry (DLLME-GC-MS) for LEV quantification
in human plasma. However, due to the matrix complexity a previous purification step is required. Unlike other pretreatment
techniques presented in the literature, for the first time, a procedure employing ultrafiltration tubes Amicon (10 kDa porous
size) without organic solvent consumption was developed. GC-MS analyses were carried out using a linear temperature program,
capillary fused silica column, and helium as the carrier gas. DLLME optimized parameters were type and volume of extraction
and dispersing solvents, salt addition, and vortex agitation time. Under chosen parameters (extraction solvent: chloroform, 130𝜇L;
dispersing solvent: isopropyl alcohol, 400𝜇L; no salt addition and no vortex agitation time), the method was completely validated
and all parameters were in agreement with the literature recommendations. LEV was quantified in patient’s plasma sample using
less than 550 𝜇L of organic solvent.
1. Introduction
Levetiracetam (LEV; Figure 1(a)) belongs to a generation
of antiepileptic drugs that have been recommended for the
treatment of epilepsy as either monotherapy in the case
of partial seizures or as an adjunctive therapy for partial,
myoclonic, and tonic-clonic seizures [1–3]. In addition,
LEV exhibits benefits for other neurologic and psychiatric
disorders, such as autism, anxiety, and bipolar disorders
[1]. A unique pharmacokinetic profile [4–6] and multiple
mechanisms of action have differentiated LEV from other
antiepileptic drugs [3, 7]. According to the Subcommittee
of the International League Against Epilepsy, the thera-
peutic plasmatic concentration of LEV was set from 12 to
46mg L−1 [5, 8]. However, concentrations of LEV outside
this range can be measured in special groups, such as elderly
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Figure 1: Chemical structures: (a) levetiracetam and (b) carbamazepine (IS).
people, pediatric populations, pregnant patients, and patients
with renal impairment. These situations could modify the
expected plasma concentration, which may lead to a higher
and toxic level of LEV [5].
Chromatographic methods for the quantification of LEV
in biological matrices have been reported. These methods
include high-performance liquid chromatography (HPLC)
and gas chromatography (GC)with various detection systems
[9–24]. Moreover, previously reported methods are mainly
based on the conventional sample preparation procedure
such as liquid-liquid extraction (LLE), solid-phase extraction
(SPE), and plasmatic protein precipitation (PPP) [9–23]. The
PPP procedure is considered a fast and easy method to
remove the plasmatic protein; however, this procedure can
result in signal suppression when liquid chromatography
coupled to mass spectrometry (LC/MS) is used due to the
presence of a precipitation agent, the coprecipitation of
interfering species, and a lack of selectivity. In addition, the
target analyte(s) may be occluded in the protein pellets [25].
The LLE procedure usually requires more consumption of
hazardous solvents, is tedious, and involves multiple steps
[26, 27]. Conversely, SPE is a more selective technique, so
the ionization suppression is seldom observed. On the other
hand, the cartridges used for the extraction are relatively
expensive. Additionally, carryover or cross-contamination
can occur [27].
Since 90s, analytical chemists have focused on the devel-
opment of the new novel sample preparation techniques,
highlighting the microextraction procedures. In general, the
microextractions require low consumption of sample and
organic solvents; besides they present adequate selectivity,
high preenrichment, and suitable cleanup procedure.
Introduced in 2006 by Rezaee and collaborators, DLLME
has received special attention in the analytical chemical field.
It is a miniaturized kind of LLE which requires microliters of
extraction solvent [28].The principle consists of a ternary sol-
vent system composed of sample (aqueous phase), extraction
solvent, and dispersing solvent.Themixture of the extraction
and dispersing solvent is quickly injected by microsyringe
into the sample, containing the target analyte, creating a
cloudy state due to themicrodroplets of the extraction solvent
dispersed into the aqueous phase. At this moment, a large
surface area is formed between the fine droplets of the extrac-
tion solvent and the aqueous phase, the analyte transference
toward the extraction phase occurring almost instantly [27–
30]. After the centrifugation step, the extraction solvent
microdroplets are sedimented at the bottom of the extraction
tube and further collected by microsyringe and afterwards
analyzed by an appropriate analytical technique [31].
This microextraction procedure has been widely devel-
oped to extract organic compounds from simple aque-
ous samples [30]. Nevertheless, there are not many works
employing highly complex matrix [31]. For this purpose, this
work will employ for the first time the DLLME to quantify an
antiepileptic drug from human plasma by GC-MS.
2. Experimental
2.1. Chemicals, Reagents, and Standard Solutions. Standard
stock solution of LEV purchased from Sigma Aldrich (St.
Louis, MO, USA) was prepared at the concentration of
1mgmL−1 in methanol. Appropriate dilutions were then
made with methanol to obtain working stock solutions at
concentrations range of 20-800𝜇gmL−1. By spiking drug-
free human plasma with the working solutions we obtained
seven calibration standards (CS) and five levels of quality
control (QC) defined by low (LQC), medium (MQC), and
high (HQC) samples and the lowest limit (LLOQ) and upper
limit (ULOQ) of quantification. The calibration curve was
prepared at the concentrations of 2.0 (LLOQ), 4.0 (LQC),
10.0, 20.0, 40.0 (MQC), 60.0 (HQC), and 80.0 (ULOQ)
𝜇gmL−1 in human plasma. A solution of carbamazepine
(CBZ; Figure 1(b)) at the concentration of 100𝜇gmL−1 was
selected as internal standard (IS) (Sigma Aldrich, St. Louis,
MO, USA). All these solutions were stored at −20∘C in glass
tubes.
The reagents (analytical grade) were dichloromethane
and acetone, both acquired fromMacronChemicals (Philips-
burg, NJ, USA). Acetonitrile and chloroethylene were pur-
chased from Synth (Diadema, SP, Brazil). Methanol, carbon
tetrachloride, and isopropyl alcohol were acquired from JT
Baker (Philipsburg, NJ, USA). Chloroform was acquired
from Tedia (Fairfield, CT, USA) and sodium chloride was
purchased from Merck (Darmstadt, Germany). Water used
to prepare the solutions was purified using a Milli-Q Plus
System (Millipore, Bedford, USA).
2.2. GC System and Analytical Conditions. The GC-MS sys-
tem used during the analyses was composed of a GC-2010
plus Gas Chromatograph coupled to a mass spectrome-
try model QP2010 Series Plus system equipped with an
autosampler model AOC20i, with electron impact (70 eV)
as the ionization source, all of which were obtained from
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ShimadzuTechnologies (Kyoto, Japan).The chromatographic
separations were made using Rtx-5ms (5% phenyl/95%
dimethyl polysiloxane, 30m length × 0.25mm i.d, 0.25 𝜇m
film thickness) fused silica capillary columns from SGE
Analytical Science (Ringwood, Australia). The injection and
ionization source temperatures were 250∘C and 220∘C. The
initial temperature of the column oven was 150∘C. The
column temperature was then programmed to increase to
230∘C at a rate of 20∘Cmin−1, at which point it was held
for 2min before finally being increased by 20∘Cmin−1 to
270∘C (and again held for 1min). The column flow rate using
pure helium (99.999%) was set at 1mLmin−1, and the total
analytical time was 9min. Simultaneously, the full scanmode
was obtained over a mass range from m/z 40 to 400 to
confirm the identification of the analytes. Quantification of
LEV and the IS was carried out in selected ion monitoring
(SIM) mode at the following mass/charge (m/z) ratios: m/z
123 for LEV andm/z 193 for the IS. LabSolution 2.53 software
from Shimadzu was used to control the GC-MS system and
for data acquisition.
2.3. Plasma Samples. The Ethics Committee of the College of
Pharmaceutical Sciences from Ribeira˜o Preto, University of
Sa˜o Paulo (protocol number 898.318), approved the protocol
for this study. The Hemotherapy Center of Ribeira˜o Preto
donated drug-free plasma samples from healthy volunteers.
A patient treated with LEV received all information about
the study protocol and gave written informed consent to
participate in the research. Blood samples of patients treated
with LEV (±5mL) were collected in a Vacutainer heparinized
tube (Becton Dickinson, Meylan, France) and centrifuged at
1800×g for 5min. After separation of the plasma sample, it
was stored in a polypropylene tube and kept frozen at −20∘C
until the analysis.
2.4. Sample Preparation
2.4.1. Ultrafiltration Procedure. In conical bottom glass tubes
(𝑛 = 4) 500 𝜇L of human plasma sample, 50 𝜇L of
the LEV solution (400 𝜇gmL−1), 50 𝜇L of the IS solution
(100 𝜇gmL−1), and 1.0mL of ultrapure water were added.
The tubes were vortex for 1 minute and this solution was
transferred to a 15mL Amicon ultrafiltration tube with a
membrane of 10 kDa porous size from Millipore (Darm-
stadt, Germany). These ultrafiltration tubes were centrifuged
at 1800×g for 20 minutes using a CF-15 centrifuge (Hitachi
Koki, Kyoto, Japan). Then, 1.0mL of the permeated phase
(aqueous solution containing LEV and IS) was transferred to
a conical bottom glass tube for further DLLME optimization
procedures. So the Amicon ultrafiltration tubes were reused
among the analysis. In order to assess the carryover effect,
an aliquot of 500𝜇L of human plasma sample and 1100 𝜇L of
ultrapure water were added in Amicon ultrafiltration tubes,
after DLLME extraction of ULOQ solution, and centrifuged
at 1800×g for 20 minutes (blank plasma samples). The
permeated phase was subjected to DLLME procedure. The
washing procedure of Amicon ultrafiltration tubes consisted
of the use of ultrapure water at least four times.
2.4.2. DLLME. For DLLME procedure, an aliquot of 1.0mL
of pretreated plasma (described in Section 2.4.1) samples
was added in a 10mL conical bottom glass tube. 400𝜇L of
isopropyl alcohol (dispersing solvent) containing 130 𝜇L of
chloroform (extraction solvent) was injected rapidly into the
aqueous phase with a 1.0mL microsyringe (Gastight, Hamil-
ton, Reno, NV, USA). At the samemoment, a cloudy solution
(aqueous phase/extraction solvent/dispersing solvent) was
quickly formed in the conical tube. So the conical tube was
subjected to centrifugation at 1800×g for 5 minutes. After
centrifugation, fine droplets of the extraction solvent were
concentrated in the bottom of the tube (sedimented phase).
The volume of the sedimented phase (𝜇L) was determined,
and the solution was transferred to a clean tube for solvent
evaporation under a gentle stream of compressed air. The
residue was solubilized in 200𝜇L of methanol, and 1 𝜇L of the
sample was injected into the GC-MS system. The procedure
is summarized in Figure 2.
All optimization parameters, such as the type of extrac-
tion and dispersing solvents, the volume of extraction and
dispersing solvents, the ionic strength, and the vortex agita-
tion time (assisted DLLME), were applied in quadruplicate
experiments (𝑛 = 4). The extraction efficiency was deter-
mined by plotting the peak area of LEV versus the evaluated
parameter.The results of each parameter were analyzed using
theMinitab 14.0 statistical program (State College, PA, USA).
2.5. Validation Method. Validation method was carried out
according to the EMA guidelines on bioanalytical method
validation [45]. The method linearity was evaluated by
employing seven different concentrations of LEV in quadru-
plicate (𝑛 = 4), and the results were weighted by 1/𝑥. A
calibration curve was obtained by spiking 500𝜇L of human
plasma with 50 𝜇L of the standard solution of LEV, 50 𝜇L of
the IS, and 1.0mL of ultrapure water. This solution was sub-
mitted to ultrafiltration procedure (described in Section 2.4.1)
and then DLLME procedure (described in Section 2.4.2).The
calibration curve range was from 2 to 80𝜇gmL−1. Linear
regression was performed by plotting the peak area ratios
between LEV and the IS versus the LEV concentrations.
After that, the statistical parameters of the calibration curve
were calculated by analysis of variance (ANOVA) and linear
regression [32, 46].
The lower limit of quantification (LLOQ) of the method
was also evaluated and it was defined as the lowest concen-
tration that can be quantified reliably with an accuracy and
precision below 20% of a nominal value [45].
Within-day accuracy and precision were evaluated using
five replicates (𝑛 = 5), in which 500𝜇L of plasma samples was
spiked with a minimum of four concentration levels covering
the calibration curve range (LLOQ, LQC, MQC, and HQC)
of the standard solution of LEV. Between-day precision and
accuracy were assessed for at least three consecutive days
of operation. The precision and accuracy parameters were
expressed as relative standard deviation (RSD, %) and as
percentage of relative error (RE, %), respectively [45].
The selectivity was assessed by analyzing six individual
sources of the blankmatrix (drug-free human plasma), which
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Figure 2: Steps of DLLME procedure.
included four normal plasma sources, a hemolyzed plasma
source, and a hyperlipidemic plasma source in order to
verify that no endogenous peak would interfere in the LEV
and the IS signals under the GC-MS conditions previously
established [45].
The carryover parameter was assessed by injecting blank
plasma samples (without the standard LEV spike) after
injecting the calibration LEV standard at the upper limit of
quantification (80 𝜇gmL−1). According to the EMA (2011),
the carryover effect on the blank sample should not be greater
than 20% of the LOQ and 5% for the IS [45].
The stability parameterwas determined in order to ensure
that the concentration of LEV had not been affected by
the storage conditions to which the analyte was subjected.
Therefore, the following stability tests were performed: (i)
freeze (−20∘C)/thaw (22 ± 2∘C) cycles, (ii) short-term room
temperature conditions (8 h on the bench-top), and (iii)
autoinjector conditions (24 hours, 22 ± 2∘C). To conduct the
stability tests, 500 𝜇L of human plasma was spiked with LEV
at a LQC (4.0 𝜇gmL−1) and at a HQC (60.0 𝜇gmL−1). After
submitting samples at storage and preparation conditions,
the IS was added and developed ultrafiltration and DLLME
procedures with the replicates. The LEV concentrations
obtained from the stability tests were compared with the
LEV concentrations obtained from freshly prepared samples
(𝑛 = 4). The samples were considered stable if the mean
concentrations at each concentrationwere within±15% of the
nominal concentration value [45].
3. Results and Discussion
3.1. Chromatographic Separation. To date, no method has
been described in the literature for the quantification of LEV
from human plasma by GC-MS. One of the aims of this
work was to develop a sensitive, selective, fast, and accurate
methodology for plasmaLEVanalysis employing theDLLME
as sample preparation technique. Based on that goal, a GC
system with electron impact as the ionization source and an
Rtx-5ms fused silica capillary column was employed. The IS
chosen for analysis wasCBZ solution prepared at 100𝜇gmL−1
in methanol. The initial oven temperature was 150∘C, and
then it was increased by 20∘C/min to 230∘C (held for 2min)
and reached a final temperature of 270∘C (held for 1min).
Under these chromatographic conditions, the retention times
were 4.2min and 7.2min for LEV and the IS, respectively.
However, several ramping speeds and temperatures were
evaluated in order to obtain a GC run-time that was as short
as possible.
Initially, the SIM-mode chosen for the quantification of
single ionswasm/z 126 for LEV andm/z 193 for the IS. During
the selectivity evaluation, a blank sample was injected and
the peaks from endogenous compounds of human plasma
sample were eluted at the same time of LEV (4.2min) using
SIM-mode m/z 126. Based on this result, another single ion
m/z 123 was selected for further analysis of LEV, and no peaks
from endogenous compounds were observed at the retention
time of LEV or the IS.
3.2. Ultrafiltration Procedure. DLLME procedure is a tech-
nique widely employed to extract analytes from environmen-
tal samples but it is seldom applied for the extraction of
analytes from biological samples. Endogenous compounds
from a biological matrix could interact with organic solvents,
and a suitable sedimented phase could not be formed [28].
Some strategies have been adopted to remove the influence
of this matrix during the DLLME procedure. Mashayekhi et
al. [32] reported the DLLME procedure for the quantification
of CBZwhere a suitable amount of acetonitrile was employed
to reduce the matrix effect and then centrifuged was done.
After filtering, dilution was done ten times for the DLLME
procedure. In the same way, Rezaee et al. [25] carried out
the determination of letrozole in human plasma. Adopted
different approaches of pretreatment as well as DLLME
application in biological matrices were showed in Table 1.
Different from the previous published papers, this work
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presents for the first time the use of ultrafiltration procedure
as previous treatment of human plasma of DLLME.
Ultrafilters were successfully applied to reduce the matrix
effect of the plasma samples. A limpid aqueous phase,
nominated permeated phase, was obtained. Therefore, a new
pretreatment for complex matrix by DLLMEwas introduced,
without adding organic solvent, resulting in less waste and,
consequently, diminishing the environmental concern.
So 500𝜇L aliquot of the plasma sample, which was previ-
ously spiked with the LEV standard solution (400𝜇gmL−1)
and the IS solution (100 𝜇gmL−1), and 1.0mL of ultrapure
water were placed into Amicon ultrafiltration tubes and cen-
trifuged at 1800×g for 20 minutes. Afterwards, 1.0mL of the
permeated phase, containing LEV and IS, was transferred to
a conical bottom glass tube for further DLLME optimization.
Membrane of the Amicon ultrafiltration tubes was porous
with 10 kDa size which it enables it to block the plasmatic
proteins and permit the passage of the LEV and IS due to low
size of molecules, 170 and 236 daltons, respectively.
The Amicon ultrafiltration tubes were reused during
developing of the method. The washing procedure consisted
of the use of ultrapure water at least four times to remove the
plasma proteins. Further, the method assessed the carryover
effect of the membranes of Amicon ultrafiltration tubes. So
a blank plasma sample (without LEV and IS) was processed
in ultrafiltration tubes previously used with ULOQ of LEV,
in quadruplicate. There was no carryover effect among
the analysis. So the washing procedure was suitable, once
precision and accuracy values were in agreement with the
specification of the regulatory agency.
3.3. DLLME. LEV is an antiepileptic drug novel with polar
nature and it is fairly challenging for DLLME technique. LEV
presents a significant tendency to remain in the aqueous
phase once it has low octanol-water partition coefficient
[33]. Nevertheless, the drug shows that it is freely soluble
in chloroform and methanol, soluble in ethanol, sparingly
soluble in acetonitrile, and practically insoluble in n-hexane
[4]. However, there is possibility to extract the drug from
aqueous phase.
In order to reach the best extraction efficiency of LEV,
type and volume of the extraction and dispersing sol-
vents, ionic strength, and the vortex agitation time (assisted
DLLME) were optimized. All of these DLLME parameters
evaluated were carried out in quadruplicate (𝑛 = 4). The
applicability of the developed method was confirmed by
checking a plasma sample from a patient who had daily taken
LEV.
3.3.1. Selection of Extraction Solvent. The selection of the
extraction solvent type is a fundamental step in the DLLME
procedure [32]. During this step, it is highly important to
choose solvents with a higher density than water and a
low solubility in water that shows good chromatographic
behavior and extraction capability for the analyte of interest
[34, 35]. Chlorinated solvents, such as dichloromethane,
tetrachloroethylene, carbon tetrachloride, and chloroform,
show these characteristics.The effect of these solvents on LEV
extraction was observed by using a fixed volume of 210𝜇L of
methanol (dispersing solvent) combined with 90𝜇L of each
chlorinated solvent. This mixture was injected directly by
syringe into 1.0mL of the permeated phase containing the
analyte of interest and the IS. During these experiments, a low
volume of the sedimented phase was observed when carbon
tetrachloride was used as the extraction solvent, which pre-
vents this sample from being further collected and analyzed.
Chloroform showed higher extraction efficiency probably
because LEV is highly soluble in chloroform (Figure 3(a)).
Therefore, chloroform was chosen as the extraction solvent
for the subsequent DLLME optimization.
3.3.2. Selection of Dispersing Solvent. The most important
point for the choice of a dispersing solvent is its miscibility in
both aqueous phase and organic phase [25]. Thereby, 210 𝜇L
of each selected dispersing solvent, methanol, acetonitrile,
acetone, and isopropyl alcohol, was evaluatedmixing 90𝜇L of
chloroform. Excluding isopropyl alcohol, all other dispersing
solvents demonstrated similar extraction efficiency for LEV
in human plasma (Figure 3(b)). Isopropyl alcohol assisted
in the dispersion of the extraction solvent inside aqueous
phase, leading a formation of an adequate cloudy state [47–
49]. However, it was selected for further experiments once it
showed the best efficiency of extraction of LEV.
3.3.3. Effect of Extraction Solvent Volume. The influence of
the volume of chloroform was evaluated in the following
range while keeping the volume of isopropyl alcohol constant
(210 𝜇L): 50, 90, 130, and 170 𝜇L. After the addition of 50𝜇L
of chloroform into the aqueous phase, a very low amount
of sedimented phase was formed. Due to the low volume of
the sedimented phase, the reproducibility was poor, making
it impossible to use this amount of extraction solvent for
quantitative analysis.The difficulty in collecting low amounts
of the sedimented phase has been previously reported by
Lo´pez-Nogueroles et al. [48]. Nevertheless, by adding 130 𝜇L
and 170 𝜇L of chloroform, the area peaks associated with
LEV were compared using analysis of variance (ANOVA).
There was no statistically significant difference considering a
confidence level of 0.05. Therefore, 130𝜇L of chloroform was
chosen to perform the DLLME procedure (Figure 3(c)).
3.3.4. Effect of Dispersing Solvent Volume. To verify the
effect of dispersing solvent volumes was investigated by
mixing 130 𝜇L of chloroform with 200, 300, 350, 400, and
500𝜇L of the isopropyl alcohol and then rapidly injecting
the samples into 1.0mL of the aqueous phase. The results
demonstrated that the extraction efficiency of LEV slightly
increased after the addition of isopropyl alcohol in amounts
from 200 to 350𝜇L. The maximum value was reached when
adding 400𝜇L of isopropyl alcohol (Figure 3(d)). Probably
at lower volumes of isopropyl alcohol (less than 400𝜇L), the
cloudy state did not form very well, and thus, the extraction
efficiency of LEV decreased. Furthermore, it seems that by
further increasing the isopropyl alcohol volume (more than
400 𝜇L), no statistically significant differencewas observed by
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Figure 3: Optimization of DLLME procedure: (a) extraction solvent type, (b) dispersing solvent type, (c) extraction solvent (chloroform)
volume, (d) dispersing solvent (isopropyl alcohol) volume, (e) vortex agitation time, and (f) salt addition.
ANOVA (𝑃 > 0.05). Therefore, 400 𝜇L of isopropyl alcohol
was selected for further optimization.
3.3.5. Effect of Vortex Agitation Time. In addition to the
features of othermicroextraction techniques, DLLMEhas the
advantage of saving time [29]. This is due to the extremely
large surface area between the aqueous and extraction phases;
therefore, the equilibrium state can be achieved quickly (a
few seconds), and the analyte transfer is almost immediate
from the aqueous phase to the extraction phase [25, 28, 30,
47]. To increase the extraction efficiency of LEV, vortex-
mixing after the formation of the cloudy mixture has been
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Table 2: DLLME parameters.
Optimized parameters Definedconditions
Dispersing solvent types
Methanol, isopropyl
alcohol, acetonitrile, and
acetone
Isopropyl
alcohol
Extraction solvent types
Chloroform,
dichloromethane,
carbon tetrachloride,
and tetrachloroethylene
Chloroform
Dispersing solvent
volumes (𝜇L)
200, 300, 350, 400, and
500 400
Extraction solvent
volumes (𝜇L) 50, 90, 130, and 170 130
NaCl concentration (%) 0–10 0
Type of shaking
(seconds) 0–30 0
proposed (assisted DLLME). The agitation time varied from
10 to 30 seconds after the cloudy state formation. The results
showed no statistically significant difference (ANOVA, 𝑃 >
0.05) when compared with the tubes without vortex agitation
(Figure 3(e)). Therefore, the extraction time was defined as
the time after injecting the mixture of extraction/dispersing
solvent into the aqueous phase until centrifugation without
vortex-mixing.
3.3.6. Salt Addition. In the DLLME procedure, the salting-
out effect was assessed by adding NaCl ranging from 3 to 10%
(w/v) to the aqueous phase in order to increase the extraction
efficiency of LEV from human plasma (Figure 3(f)). Water
molecules form hydrated spheres around the salt ions, thus
reducing the water quantity available to dissolve the target
analyte and thereby leading the analyte molecules to the
extraction solvent [36, 50]. However, in competition with
this process, polar molecules such as LEV can participate
in electrostatic interactions with the salt ions in solution
and can consequently reduce the ability of the analyte to
transfer to the organic solvent droplets [36, 50]. As a result,
the subsequent experiments were carried out without the
addition of salt. Once the mixture reached a cloudy state
(formation of a large surface area), the centrifugation step
was a fundamental procedure to separate both the aqueous
and the extraction systems. According to previous studies,
centrifugation times greater than 5.0minutes do not promote
higher efficiencies of the extraction [47].Therefore, 5minutes
and 1800×g were set as suitable conditions for achieving
the separation of the sedimented phase and promoting good
extraction efficiency. The final conditions for the DLLME
procedure are summarized in Table 2.
3.4. Validation Method. Linearity of the analytical method
was investigated by employing seven concentrations of LEV
in four replicates.Thus, an aliquot of 500𝜇L of human plasma
samples spiked with 50 𝜇L of LEV and 50 𝜇L of IS in order to
obtain the final concentrations of 2 (LLOQ), 4 (LQC), 10, 20,
Table 3: Linearity and limit of quantification of the LEVmethod for
analyses of human plasma.
Parameters LEV
Slopea 0.0040
Interceptb 0.0011
Regression coefficient (𝑟) 0.9988
Linear range (𝜇gmL−1) 2–80
Experimental 𝐹 valueb 1.15
𝑃 value 0.37
LLOQ (𝜇gmL−1) 2
Precision (RSD, %) 5.8
Accuracy (RE, %) 0.7
aCalibration curves were prepared in quadruplicate (𝑛 = 4) for concentra-
tions of 2, 4, 10, 20, 40, 60, and 80𝜇gmL−1; 𝑦 = 𝐴𝑥 + 𝐵, where 𝑦 is the ratio
between the analyte peak area and the IS peak area; 𝐴 is the slope, 𝐵 is the
intercept, and 𝑥 is the concentration of the measured solution in 𝜇gmL−1;
bexperimental 𝐹value < 𝐹crit,95% = 2.84.
40 (MQC), 60 (HQC), and 80 (ULOQ) 𝜇gmL−1 of LEV and
10 𝜇gmL−1 of CBZ. So, 1.0mL of ultrapure water was added
and the conical glass tubes were submitted to vortex for 1
minute. The solution was transferred to Amicon ultrafiltra-
tion tubes and it was centrifuged at 1800×g for 20 minutes.
Afterwards, DLLME (described in Section 2.4.2) procedure
was developed in 1.0mL of obtained permeated phase. The
results were weighted (1/𝑥) because the residual analysis of
the analytical curve showed heteroscedasticity behavior. The
curve calibration was linear over the concentration range
from 2 to 80 𝜇gmL−1. The linear equation calculated by the
least squares method was 𝑦 = 0.0040𝑥 + 0.0011 (𝑟 = 0.9988;
RE = 0.7%; RSD = 5.8%). The results are showed in Table 3.
According to theAMC(AnalyticalMethodsCommittee) [51],
a value of the regression coefficient (𝑟) close to unity is not
necessarily the outcome of a linear relationship. Thus, a test
for the lack of fit should be performed [52].This test evaluates
the variance of the residual values for each concentration
[53]. For lack of fit, the calculated 𝐹 value (1.15) was smaller
than the tabulated 𝐹 value (2.84) and the 𝑃 value was higher
than 0.05 (95% significance level), whereas for the linear
regression model, the calculated 𝐹 value (4931.71) was higher
than tabulated 𝐹 value (2.85) and its 𝑃 value was smaller
than 0.05 (95% significance level), as determined by ANOVA.
According to the statistical tests, the outcome of the analysis
by the regression method is linear and showed no lack of fit
(Table 4).
The within- and between-days precision and accuracy
evaluated for at least four concentrations of the LEV standard,
in quintuplicate, are given in Table 5. Then, the measured
concentration at each concentration level was within ±15% of
the nominal concentration and for the LLOQ within ±20%.
Stability tests assured the LEV stability in the biological
matrix. Therefore, all tests performed, such as the freeze
and thaw cycles, short-term room temperature conditions,
and autoinjector conditions (Table 6) showed no significant
instability.
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Table 4: ANOVA results for the linearity of LEV (SS: sum of squares; Df: degrees of freedom; MS: mean squares; 𝐹calc: calculated 𝐹 test; 𝐹tab:
tabulated 𝐹 test).
ANOVA SS Df MS 𝐹calc 𝑃 value
a 𝐹tab
Regression model 0.26854 1 0.26854 4931.71 0.000 2.85
Residual error 0.00103 19 0.00005 Linear
Lack of fit 0.00030 5 0.00006 1.15 0.379 2.84
Pure error 0.00073 14 0.00005 No lack of fit
a𝑃 value: significance level of 0.05.
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Figure 4: GC-MS chromatograms obtained from the analysis of an extracted patient plasma sample: (a) patient sample after the levetiracetam
intake (plasma concentration of levetiracetam was 25𝜇gmL−1) and (b) a drug-free plasma sample; SIMmode is (I) m/z 123 and (II) m/z 193.
Table 5: Within- and between-days accuracy and precision.
Analyte
Nominal
concentration
(𝜇gmL−1)
Measured
concentration
(𝜇gmL−1)
Precision
RSDa (%)
Accuracy
REa (%)
Within-day
LEV
2.0 1.9 10.6 −3.1
4.0 4.1 11.4 3.1
40.0 38.0 7.6 −5.0
60.0 57.8 8.9 −3.6
Between-day
LEV
2.0 2.0 4.6 1.6
4.0 4.2 −8.1 5.1
40.0 39.1 3.0 −2.4
60.0 61.6 4.0 2.6
aRSD, relative error deviation expressed as percentage (%).
bRE, relative error expressed as percentage (%).
4. Method Application and
Comparison to Other Methods
The analytical parameters of the proposed method have been
compared to earlier reported methods for the quantitation
of LEV. Greiner-Sosanko et al. [21] described a GC-NPD
method where the linear range was from 2.5 to 45𝜇gmL−1.
Our developed method presented a wider linear range
compared to this previous method. The GC-MS method
developed by Isoherranen et al. [9] showed a total run-time
for the LEV of 14.7min, which is longer time than our pro-
posed run-time (9.0min). Until this moment, the literature
has no described method to quantify LEV from biological
sample using a miniaturized sample preparation technique.
In this regard, DLLME procedure was able to promote a
suitable cleanup procedure of the biological samples and to
extract the LEV despite its polar nature from aqueous phase
employing only 130 𝜇L of chloroform. Previously to DLLME,
the ultrafiltration procedure was employed for the first time
to remove endogenous compounds from the plasma allowing
accomplishment of the DLLME procedure, even in complex
matrix. Unlike other pretreatments described in the literature
for DLLME, this one does not require the use of any organic
solvents. The ultrafilters were reused among analysis after
checking carryover effect.
The proposed analytical method was used to analyze a
human plasma sample from a patient who had taken LEV
(1000mg once per day) in order to evaluate its applica-
bility. Patient plasma samples and drug-free plasma were
extracted under optimized conditions (𝑛 = 3), and their
chromatograms are shown in Figure 4.The plasmatic concen-
tration of LEV in the patient was 25𝜇gmL−1 (RSD = 3.2%
and RE = 5.6%), demonstrating it is within the therapeutic
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Table 6: Stability assays (𝑛 = 4) of the developed method.
Nominal concentration
(𝜇gmL−1)
Short-term room temperature
(8 h) Autoinjector (24 h)
Freeze and thaw cycles (12 h, 3
cycles)
Accuracy
REa (%)
Precision
RSDb (%)
Accuracy
REa (%)
Precision
RSDb (%)
Accuracy
REa (%)
Precision
RSDb (%)
4.0 2.3 2.4 4.2 2.5 1.6 3.2
60 5.2 4.3 5.6 4.2 5.8 4.1
aRE, relative error expressed as percentage (%).
bRSD, relative error deviation expressed as percentage (%).
range.Therefore, the developedmethod has successfully been
applied in the therapeuticmonitoring of a patient taking LEV.
5. Concluding Remarks
For the first time, an analytical method has been described
employing DLLME/GC-MS for the determination of LEV in
human plasma. The chromatographic separation was very
simple, fast, easy to operate, accurate, and precise. Addi-
tionally, this work has demonstrated an alternative cleanup
pretreatment able to remove endogenous interferences from
the plasma sample without the use of any organic solvents.
During all DLLME-GC-MS presented here, low organic
solvent consumption (𝜇L) has been required to analyze a
complex matrix, and consequently the operational costs of
the process have been reduced, as well as the low waste
generation.
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